GlykoGen
GlykoGen is developing a pipeline of anti-glycan antibodies to target ‘hard to treat’ cancers, including pancreatic cancer, using a novel selection process to prepare recombinant antibodies. GlykoGen’s vision is the delivery of more effective therapies for cancer, targeting cancer cells through their surface glycans. Glycans are of interest in the study of cancer because they play a key role in the function of cell surface glycoprotein, impacting the unique phenotypes of cancer cells. Glycans are thought to be directly relevant cancer progression and therefore to treatment. However the difficulties of producing antibodies to glycans has meant that their therapeutic potential in cancer remains to be exploited.
